Real‐World Data Analysis of Genomic Alterations Detected by a Dual DNA – RNA Comprehensive Genomic Profiling Test
Cancer Science · 2025-07 · 116 (7) · 1984-1995
DOI: 10.1111/cas.70071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 26.03.2025. Verfasst von Kousuke Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms, Genomics. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
GenMineTOP, the first dual DNA–RNA comprehensive genomic profiling (CGP) test in Japan, was approved for reimbursement in 2023. To evaluate its clinical utility, we analyzed 1356 cases from the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) database. Oncogenic genomic alterations were identified in 91.5% of cases. Somatic mutations were the most prevalent, followed by amplifications and fusion/exon skipping events. The DNA panel, covering 737 genes, detected not only alterations relevant to therapeutic decisions but also those providing insights into tumor biology. Among the latter, frequently observed examples included mutations in KMT2C ( n = 28) and ARID1B ( n = 24), and amplifications in GLI1 ( n = 14) and YAP1 ( n = 10), which are not included in other CGP tests approved in Japan. The RNA panel identified 105 fusion events, including 11 NTRK fusions (0.8%), of which five were NTRK3 fusions: two with the well‐known ETV6 ‐ NTRK3 fusion and three with non‐ ETV6 partners. Forty‐nine of these fusions were diagnostically significant, highlighting the utility of the RNA panel. Amplification‐RNA expression analyses revealed strong correlations for MDM2 , CDK4 , EGFR , and ERBB2 . In contrast, weaker correlations observed for MYC and FGFR1 highlighted the need for careful interpretation of amplification in these genes. Cancer type significantly influenced RNA expression, with KIT and TERT mutations linked to increased expression and significant overexpression observed in ALK , FGFR3 , NTRK1 , NTRK3 , and RET fusions. In summary, this study demonstrated the real‐world clinical utility of the dual DNA–RNA CGP test and provided a valuable resource for interpreting RNA expressions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
- Division of Integrative Genomics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Genome Science and Medicine Laboratory, RCAST, The University of Tokyo, Tokyo, Japan.
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Kousuke Watanabe
Zitieren
APA
Watanabe, K., Ogawa, M., Shinozaki-Ushiku, A., Tsutsumi, S., Tatsuno, K., Aburatani, H., Kage, H., & Oda, K. (2025). Real‐World Data Analysis of Genomic Alterations Detected by a Dual DNA – RNA Comprehensive Genomic Profiling Test. Cancer Science, 116(7), 1984-1995. https://doi.org/10.1111/cas.70071
Vancouver
Watanabe K, Ogawa M, Shinozaki-Ushiku A, Tsutsumi S, Tatsuno K, Aburatani H, et al. Real‐World Data Analysis of Genomic Alterations Detected by a Dual DNA – RNA Comprehensive Genomic Profiling Test. Cancer Science. 2025;116(7):1984-1995. doi:10.1111/cas.70071
BibTeX
@article{Watanabe2025,
author = {Watanabe, Kousuke and Ogawa, Miho and Shinozaki-Ushiku, Aya and Tsutsumi, Shuichi and Tatsuno, Kenji and Aburatani, Hiroyuki and Kage, Hidenori and Oda, Katsutoshi},
title = {Real‐World Data Analysis of Genomic Alterations Detected by a Dual DNA – RNA Comprehensive Genomic Profiling Test},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {7},
pages = {1984--1995},
doi = {10.1111/cas.70071}
}
EUVIMED